Evidence map›Paper›PMID 38495596›Full record

ArticleEuropean journal of inorganic chemistry2023

Construction of the Bioconjugate Py-Macrodipa-PSMA and Its In Vivo Investigations with Large

Aohan Hu, Kirsten E Martin, Dariusz Śmiłowicz, Eduardo Aluicio-Sarduy, Shelbie J Cingoranelli, Suzanne E Lapi, Jonathan W Engle, Eszter Boros, Justin J Wilson

Abstract read
In one paragraph

Article in European journal of inorganic chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. ImprovedACS omega · 2026
    Article
  2. Article
  3. Hydroxyquinoline-functionalised aza-crown macrocycles for lanthanide coordination.Dalton transactions (Cambridge, England : 2003) · 2026
    Article
  4. Review
  5. Article
  6. Chelation of [Dalton transactions (Cambridge, England : 2003) · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aohan HuDepartment of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, USA.
Kirsten E MartinDepartment of Chemistry, Stony Brook University, Stony Brook, New York 11794, USA.
Dariusz ŚmiłowiczDepartment of Chemistry, Stony Brook University, Stony Brook, New York 11794, USA.
Eduardo Aluicio-SarduyDepartment of Medical Physics and Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
Shelbie J CingoranelliDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Suzanne E LapiDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Jonathan W EngleDepartment of Medical Physics and Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
Eszter BorosDepartment of Chemistry, Stony Brook University, Stony Brook, New York 11794, USA.
Justin J WilsonDepartment of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, USA.

Funding

Chemical Biology Training InterfaceT32GM136572 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI ELIZABETH M BOON, Jessica Chuang Seeliger · 2020 to 2026
$2.9M
Chelation strategies for s-, p-, and f-block radionuclides for targeted alpha therapyR01EB029259 · NIBIB · CORNELL UNIVERSITY · PI WILSON, JUSTIN J · 2020 to 2023
$1.4M
Expanding the Therapeutic Potential of the Alpha Emitter Radium-223R21EB027282 · NIBIB · CORNELL UNIVERSITY · PI WILSON, JUSTIN J · 2019 to 2021
$619k
NIBIB NIH HHS R01 EB029259NIBIB NIH HHS R21 EB027282NIGMS NIH HHS T32 GM136572
6 · The paper itself

Abstract

To harness radiometals in clinical settings, a chelator forming a stable complex with the metal of interest and targets the desired pathological site is needed. Toward this goal, we previously reported a unique set of chelators that can stably bind to both large and small metal ions, via a conformational switch. Within this chelator class, py-macrodipa is particularly promising based on its ability to stably bind several medicinally valuable radiometals including large

Indexed as

Anticancer agentsChelatePSMARadiopharmaceuticalsRare earth

Identifiers

PMID38495596
PMCPMC10939043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.